To investigate the opportunity of entecavir treatment for HBeAg-negative acute-on-chronic liver / 中华实验和临床病毒学杂志
Chinese Journal of Experimental and Clinical Virology
; (6): 286-288, 2013.
Article
em Zh
| WPRIM
| ID: wpr-318040
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To explore relations between the opportunities and effects of internal general treatment added Entecavir on acute-on-chronic liver failure (ACLF) of HBeAg-negative chronic hepatitis B in different score ranges of acute-on-chronic liver failure severity.</p><p><b>METHODS</b>A total of 108 ACLF of HBeAg-negative chronic hepatitis B patients with different ACLF severity score were treated with internal general treatment added Entecavir. The liver failure severity scores, HBV-DNA loads during the initiation of therapy, recovery phase and in deathbed phase, courses of Entecavir administration and mortalities were studied.</p><p><b>RESULTS</b>For 19 patients with high ACLF score (> or = 12), the difference in ACLF score between pre and post-treatment was not significant. The difference in HBV-DNA load between pre and post-treatment was not significant and the mortality was 18/19. For 30 patients with higher intermediate ACLF score (8-11), the difference in ACLF score between pre and post-treatment was not significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 66.67% (20/30). For 36 patients with lower intermediate ACLF score (5-7), the difference in ACLF score between pre and posttreatment was not significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 30.56% (11/36). For 23 patients with low ACLF score (< or = 4), the difference in ACLF score between pre and post-treatment was significant. The difference in HBV-DNA load between pre and post-treatment was significant, and the mortality was 8.70% (2/23).</p><p><b>CONCLUSIONS</b>A novel acute-on-chronic liver failure scoring system can syllabify differentiate the relations between the opportunities and efficacies on the Entecavir treatment for HBeAg-negative ACLF.</p>
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Antivirais
/
Virologia
/
Sangue
/
Vírus da Hepatite B
/
Falência Hepática
/
Hepatite B Crônica
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Genética
/
Guanina
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Chinese Journal of Experimental and Clinical Virology
Ano de publicação:
2013
Tipo de documento:
Article